Summary & Overview
HCPCS S0126: Injection, follitropin alfa, 75 IU
HCPCS Level II code S0126 denotes an injection of follitropin alfa, 75 IU, a recombinant follicle-stimulating hormone used in assisted reproduction to stimulate ovarian follicle growth. Nationally, this code matters for both clinical fertility practice workflows and payers' coverage determinations because injectable fertility medications are high-cost, frequently billed items with important implications for benefit design and prior authorization processes.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how S0126 is used in clinical settings, where the service is typically delivered, and which payers commonly handle claims for this drug. The publication provides benchmarks for utilization and coding patterns, summaries of relevant payer policy considerations, and clinical context about the medication's role in controlled ovarian stimulation.
The report highlights coding specifics, common modifiers listed for this code, and notes on sites of service. Where payer-specific policies or coverage limits exist, those differences are summarized to help billing, reimbursement, and clinical teams understand administrative expectations. Data not available in the input will be clearly noted in sections that require additional details.
Billing Code Overview
HCPCS Level II code S0126 represents an injection of follitropin alfa, 75 IU. This service is a hormonal injectable used in reproductive medicine to stimulate ovarian follicle development. The service type is an injectable medication administration for fertility treatment. The typical site of service for S0126 is outpatient specialty clinics such as reproductive endocrinology and infertility (REI) clinics, ambulatory infusion centers, or physician offices where fertility treatments are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a woman of reproductive age undergoing controlled ovarian stimulation as part of assisted reproductive technology (ART) such as in vitro fertilization (IVF) or intrauterine insemination (IUI). The patient presents to a fertility clinic with a diagnosis such as diminished ovarian reserve, anovulatory infertility, or unexplained infertility and is prescribed recombinant follicle-stimulating hormone (follitropin alfa) to stimulate multiple follicle development. Treatment planning includes baseline ultrasound and serum testing, dosing protocol selection, and informed consent for injectable therapy. Administration is commonly performed by the patient via subcutaneous injection at home after training by clinic nursing staff, or by clinic staff in an ambulatory infusion or injection suite when needed. Typical workflow: baseline evaluation and order entry by reproductive endocrinologist; medication dispensing from specialty pharmacy or clinic medication room; patient education and demonstration of self-injection; scheduled monitoring visits with transvaginal ultrasound and estradiol labs every 2–3 days; adjustments to dose documented in the medical record; on final trigger and oocyte retrieval planning, nursing documents administered doses of S0126 in medication administration record and links to cycle monitoring notes and procedure scheduling. Billing for S0126 reflects the unit vial of 75 IU recombinant follitropin alfa supplied per injection event.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|